OA10564A - A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane - Google Patents

A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane Download PDF

Info

Publication number
OA10564A
OA10564A OA60698A OA60698A OA10564A OA 10564 A OA10564 A OA 10564A OA 60698 A OA60698 A OA 60698A OA 60698 A OA60698 A OA 60698A OA 10564 A OA10564 A OA 10564A
Authority
OA
OAPI
Prior art keywords
vaccines
pharmaceutical preparation
antigens
preparation according
caprylic
Prior art date
Application number
OA60698A
Other languages
English (en)
Inventor
Sveinbjoern Gizurarson
Iver Heron
Original Assignee
Lyfjathroun H F
Seruminstitut Statens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun H F, Seruminstitut Statens filed Critical Lyfjathroun H F
Publication of OA10564A publication Critical patent/OA10564A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
OA60698A 1993-02-15 1995-08-11 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane OA10564A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Publications (1)

Publication Number Publication Date
OA10564A true OA10564A (en) 2002-06-20

Family

ID=8090567

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60698A OA10564A (en) 1993-02-15 1995-08-11 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane

Country Status (14)

Country Link
US (1) US5942237A (fr)
EP (1) EP0682528B1 (fr)
JP (1) JPH09508614A (fr)
AT (1) ATE195077T1 (fr)
AU (1) AU668290B2 (fr)
CA (1) CA2156084A1 (fr)
DE (1) DE69425427T2 (fr)
DK (2) DK17093D0 (fr)
ES (1) ES2150982T3 (fr)
GR (1) GR3034727T3 (fr)
NO (1) NO312057B1 (fr)
OA (1) OA10564A (fr)
PT (1) PT682528E (fr)
WO (1) WO1994017827A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
ES2185900T3 (es) * 1996-01-25 2003-05-01 Profylakse Aps Composicion farmacologica que comprende un componente p serico del amiloide para el tratamiento profilactico o terapeutico de infecciones viricas y un hit para la deteccion de union entre dicha composicion y componentes viricos.
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
JP2002511423A (ja) * 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1034792A1 (fr) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus
HUP0202846A3 (en) * 1999-09-24 2003-12-29 Smithkline Beecham Biolog Intranasal influenza virus vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2457595A1 (fr) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals Procede de production d'anticorps ex-vivo
KR100406503B1 (ko) * 2001-09-25 2003-11-19 한국과학기술연구원 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
AU2003215885B2 (en) * 2002-02-25 2008-07-03 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
WO2004047778A1 (fr) 2002-11-26 2004-06-10 Uc Tech Materiaux et procedes pour la prevention et le traitement de troubles epitheliaux a mediation microbienne
WO2005032462A2 (fr) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Traitement au glucocerebroside d'une maladie
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CN101123982B (zh) * 2005-01-28 2015-06-17 西北大学 脂质和一氧化二氮组合作为用于增强疫苗功效的佐剂
EP1871349A1 (fr) * 2005-04-11 2008-01-02 Nanobio Corporation Halogenures d'ammonium quaternaires pour le traitement de pathologies infectieuses
CA2618974C (fr) * 2005-08-09 2014-01-28 Nanobio Corporation Compositions de nanoemulsions possedant une activite anti-inflammatoire
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
EP2123296B1 (fr) * 2007-01-31 2019-05-22 Hisamitsu Pharmaceutical Co., Inc. Adjuvant pour administration transdermique ou transmucosale et preparation pharmaceutique le contenant
WO2009014782A2 (fr) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Production améliorée et assemblage in vivo de particules icosaédriques solubles recombinées analogues à un virus
EP2293813A4 (fr) 2008-05-23 2012-07-11 Univ Michigan Vaccins à nanoémulsion
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
CN102596243B (zh) * 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
ES2744454T3 (es) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Composición de adyuvante
US10525088B2 (en) 2014-05-30 2020-01-07 Kirin Holdings Kabushiki Kaisha Lactic acid bacterial immunopotentiating activity-increasing composition and method for increasing immunopotentiating activity of lactic acid bacteria
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
CN111721937B (zh) * 2019-03-29 2023-04-07 北京九强生物技术股份有限公司 人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
NL9000207A (fr) * 1990-01-29 1991-08-16 Duphar Int Res
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
WO1992018147A1 (fr) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Formulations de microemulsions a inversion de phase
CZ42894A3 (en) * 1991-08-26 1995-02-15 Scripps Research Inst Peptides inducing cytotoxic response of t lymphocytes to hepatitis b virus
CA2083553A1 (fr) * 1991-11-25 1993-05-26 Kuniharu Seki Composition immunogene

Also Published As

Publication number Publication date
NO953182D0 (no) 1995-08-14
AU668290B2 (en) 1996-04-26
NO312057B1 (no) 2002-03-11
EP0682528B1 (fr) 2000-08-02
ES2150982T3 (es) 2000-12-16
EP0682528A1 (fr) 1995-11-22
DK0682528T3 (da) 2000-12-27
JPH09508614A (ja) 1997-09-02
DK17093D0 (da) 1993-02-15
WO1994017827A1 (fr) 1994-08-18
DE69425427T2 (de) 2001-02-08
ATE195077T1 (de) 2000-08-15
US5942237A (en) 1999-08-24
PT682528E (pt) 2001-01-31
AU6106594A (en) 1994-08-29
GR3034727T3 (en) 2001-01-31
DE69425427D1 (de) 2000-09-07
CA2156084A1 (fr) 1994-08-18
NO953182L (no) 1995-10-12

Similar Documents

Publication Publication Date Title
OA10564A (en) A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane
US6391318B1 (en) Vaccine compositions including chitosan for intranasal administration and use thereof
Claassen et al. The iscom structure as an immune enhancing moiety: experience with viral systems.
Glück Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens
Newman et al. Use of nonionic block copolymers in vaccines and therapeutics
AU8459898A (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
EP0988053A1 (fr) Saponines purifiees servant d'adjuvants oraux
EP2231145B1 (fr) Compositions et procédés pour améliorer la réponse immunitaire contre des antigènes
US20020009463A1 (en) Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US6890540B1 (en) Vaccine formulation
KR20030015288A (ko) 보조제 배합물로서의 큐에스-21 및 아이엘-12
Li et al. iNKT cell agonists as vaccine adjuvants to combat infectious diseases
EP1315672A1 (fr) Composition de vecteur d'administration et procede pour l'administration d'antigenes et d'autres medicaments
AU2008360937B2 (en) Methods of enhancing adjuvanticity of vaccine compositions
Ferreira et al. Glycoside based adjuvants
McGhee et al. Oral immunization: a summary